{"resourceType": "Composition", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-report"], "versionId": "5", "lastUpdated": "2025-09-14T18:30:51.295Z"}, "contained": [{"resourceType": "PractitionerRole", "id": "PointOfContact", "practitioner": {"display": "Chief Medical Officer"}, "organization": {"display": "Eli Lilly and Company"}, "contact": [{"telecom": [{"system": "email", "value": "ClinicalTrials.gov@lilly.com"}]}, {"telecom": [{"system": "phone", "value": "800-545-5979"}]}]}], "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-description", "valueMarkdown": "An evidence report summarizing the Results Section of a ClinicalTrials.gov record entry"}], "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "267224", "assigner": {"display": "Computable Publishing LLC"}}, {"use": "official", "system": "https://clinicaltrials.gov", "value": "NCT03421379"}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379 Results Report", "assigner": {"display": "Computable Publishing LLC"}}], "status": "final", "type": {"text": "EvidenceReport"}, "category": [{"text": "ClinicalTrials.gov Study Results"}], "subject": [{"type": "ResearchStudy", "display": "A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379 FHIR Transform", "assigner": {"display": "Computable Publishing LLC"}}, "reference": "ResearchStudy/267223"}], "useContext": [{"code": {"system": "http://terminology.hl7.org/CodeSystem/usage-context-type", "code": "program", "display": "Program"}, "valueCodeableConcept": {"text": "ClinicalTrials.gov"}}], "name": "NCT03421379_Results", "title": "Results Section for NCT03421379", "relatesTo": [{"type": "derived-from", "targetUri": "https://clinicaltrials.gov/api/query/full_studies?expr=NCT03421379&max_rnk=1&fmt=JSON"}, {"type": "cite-as", "targetMarkdown": "Results Section for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267224. Revised 2025-09-14. Available at: https://fevir.net/resources/Composition/267224. Computable resource at: https://fevir.net/resources/Composition/267224#json."}], "id": "267224", "url": "https://fevir.net/resources/Composition/267224", "date": "2025-09-14T18:30:51.295Z", "custodian": {"reference": "Organization/118079", "type": "Organization", "display": "Computable Publishing LLC"}, "author": [{"display": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "section": [{"title": "Participant Flow Module", "code": {"text": "ParticipantFlowModule"}, "entry": [{"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-participant-flow-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Participant Flow Report for NCT03421379"}]}, {"title": "Baseline Characteristics Module", "code": {"text": "BaselineCharacteristicsModule"}, "entry": [{"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-baseline-measure-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Baseline Characteristics Report for NCT03421379"}]}, {"title": "Outcome Measures Module", "code": {"text": "OutcomeMeasuresModule"}, "entry": [{"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-outcome-measure-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Outcome Measures Report for NCT03421379"}]}, {"title": "Adverse Events Module", "code": {"text": "AdverseEventsModule"}, "entry": [{"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03421379-adverse-events-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Adverse Events Report for NCT03421379"}]}, {"title": "More Info Module", "code": {"text": "MoreInfoModule"}, "section": [{"title": "Certain Agreement", "code": {"text": "CertainAgreement"}, "entry": [{"display": "AgreementPISponsorEmployee False"}, {"display": "AgreementRestrictionType GT60"}, {"display": "AgreementRestrictiveAgreement True"}]}, {"title": "Point Of Contact", "code": {"text": "PointOfContact"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Chief Medical Officer, Eli Lilly and Company</div>"}, "entry": [{"reference": "#PointOfContact", "type": "PractitionerRole", "display": "Chief Medical Officer, Eli Lilly and Company"}]}]}]}